Verdict MIXED

MIXED — The FDA approved Casgevy in December 2023, and Casgevy is an oral tablet taken every day, But Not Fully

Verified on July 20, 2026

The FDA approved Casgevy in December 2023 for sickle cell disease.

Confidence70%

How strongly independent, cited sources support this verdict.

Claim reviewed

The FDA approved Casgevy in December 2023, and Casgevy is an oral tablet taken every day.

Analysis summary

The FDA approved Casgevy in December 2023 for sickle cell disease.

Evidence profile

78 / 100 weighted evidence score H:2 / M:0 / L:0

Key findings

  • The FDA approved Casgevy in December 2023 for sickle cell disease.

Sources

Analyzed across 2 independent publishers

FDA Approves First Gene Therapies to Treat Patients with ... Fda
High credibility 78/100
government_primaryInstitutional domain
FDA approves CASGEVY, the first CRISPR/Cas9 gene ... - PMC Nih
High credibility 78/100
government_primaryInstitutional domain

Citations

Copy formatted citations from the verified sources above.

Need to verify another claim?

Open Claims Radar to analyze headlines, posts, or links with live source checks.

Verify a claim
Explore more trending fact checks
Verified by Claims Radar
Possum Mattern Studios